Aktienanalyse zu AxoGen, Inc. (AXGN)AXGNAxoGen, Inc.

Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

AxoGen Inc is a good buy right now due to its strong revenue growth of 23% year-over-year in Q2 2026, reaching $69.7 million, and a positive analyst outlook with a target price of $60 from Truist. However, the company reported a net income loss of $15.16 million in Q2 2026, which poses a risk to profitability.

6 analysts cover AXGN: 6 rate it Buy, 0 Hold and 0 Sell. The average price target is 39.80.